JANX — Janux Therapeutics Income Statement
0.000.00%
Last trade - 00:00
- $2.32bn
- $1.66bn
- $8.08m
- 53
- 16
- 74
- 44
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 3.64 | 8.61 | 8.08 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Total Operating Expenses | 3.77 | 4.84 | 36.6 | 75.7 | 81.1 |
Operating Profit | -3.77 | -4.84 | -32.9 | -67.1 | -73 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -4 | -6.78 | -32.7 | -63.1 | -58.3 |
Net Income After Taxes | -4 | -6.78 | -32.7 | -63.1 | -58.3 |
Net Income Before Extraordinary Items | |||||
Net Income | -4 | -6.78 | -32.7 | -63.1 | -58.3 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -4 | -6.78 | -32.7 | -63.1 | -58.3 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.1 | -0.17 | -0.785 | -1.52 | -1.32 |
Dividends per Share |